HVTN 111

A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIV-uninfected adult participants,

Enrollment Opened

Objectives

-To evaluate safety and tolerability of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

-To evaluate  immune responses of clade C DNA and bivalent gp120 protein and MF59 adjuvant in each vaccine regimen.

Trial design

Multicenter, randomized, controlled, double-blind trial conducted in six sites in Southern African countries.

Funder/Sponsor

NIH/DAIDS HVTN

 

You can reach us at:

NIMR - Mbeya Medical Research Center
P.O Box 2410
Hospital Hill rd, Mbeya Tanzania

Tel +255 25 250 3364
Fax +255 25 250 3134

Working hours:
Mon - Fri
08:00 - 17:00 EAT (GMT + 3)

Or send us an email at This email address is being protected from spambots. You need JavaScript enabled to view it.

Our Twitter Feed

NIMRMbeya Dr. Andrew Kitua, NIMR Council Chairperson, appreciating NIMR as an institution leading in medical research that is… https://t.co/WVCMGEia5E
NIMRMbeya Naibu Katibu Mkuu @wizara_afyatz Dkt. Shekalaghe akitoa wito kuhusiana na ugonjwa wa Kifua Kikuu alipohudhuria mkut… https://t.co/W6jLLeg28x
NIMRMbeya The @TBSequel stakeholders' dissemination meeting today at @NIMRHQS under the theme "Towards programmatic diagnosis… https://t.co/AE4OIKWqvp
NIMRMbeya As we approach the @TBSequel stakeholders' dissemination meeting ⏳️ Mbeya site screened 611 pts and enroled 424 in… https://t.co/omv5esl6Im
© 2017 NIMR - Mbeya Medical Research Center